Product Description
Mechanisms of Action: IL4 Antagonist, IL13 Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aerovance
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic|Asthma
Phase 1: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00785668 |
QGUY/2007/AER 001/-04 | P1 |
Completed |
Asthma |
None |
2019-03-18 |
Treatments |
|
2007-006545-41 |
AEROVANT | P2 |
Completed |
Asthma |
2010-03-01 |
2022-03-12 |
Treatments |
|
NCT00801853 |
PPD/2007/AER 001 DPI/2b | P2 |
Completed |
Asthma |
2010-02-01 |
2019-03-18 |
Treatments |
|
NCT00676884 |
QGUY/2005/AER 001/-02 | P2 |
Completed |
Dermatitis, Atopic |
2006-07-01 |
2019-03-18 |
Treatments |